Contributor Since 2010
CytRx today released a news release stating it will be presenting at the 16th Annual BIO CEO & Investor Conference next week at the Waldorf Astoria in New York City. CytRx's President and CEO, Steven A. Kriegsman, as well as Vice President of Business Development, David Haen, will be presenting a corporate update on Monday, February 10, 2014 at 2:30 pm EST (11:30 am PST).
Among other things, the company will be covering its expanded 2014 aldoxorubicin development pipeline after its recent successful $75 million financing. Onlookers are advised to visit the company's Investors section, at: cytrx.com/investors/presentations.
CytRx is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin.
For more information, visit: cytrx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com